HoldsUp

DavidPerlmutterMD · 2025-01-06 · David Perlmutter (host), Georgia Ede

Revolutionizing Mental Health: The Rise of Metabolic Psychiatry | Dr. Georgia Ede

28 research-tied claims examined: 1 contradicted 6 overstated 3 context 16 supported 2 unverified

6

Overstated

0:21:04Georgia Edeoverstatedlow

High levels of refined carbohydrates and vegetable oils alter the kynurenine pathway through inflammation and oxidative stress, impacting neurotransmitters including serotonin, melatonin, dopamine, glutamate, and GABA.

"there is this key pathway, this key regulatory pathway in the brain, it's called the kynurenine pathway. And basically this pathway helps regulate the production and activity of a number of different neurotransmitters in the brain, a number of different chemicals, many of which are also the targets of the psychiatric medicines that we prescribe. So serotonin, melatonin, dopamine, glutamate, GABA—many different neurotransmitters are affected by this pathway. But this pathway can be thrown far out of balance by these refined carbohydrates and vegetable oils, because the refined carbohydrates and vegetable oils cause inflammation and something called oxidative stress" (said at 0:21:04)

The biological mechanisms described by the speaker are partially grounded in psychoneuroimmunology: inflammatory cytokines and oxidative stress can activate enzymes such as indoleamine 2,3-dioxygenase (IDO), shifting tryptophan metabolism away from serotonin and melatonin synthesis and down the kynurenine pathway, yielding neuroactive metabolites that interact with glutamatergic and other neurotransmitter systems. However, attributing specific, pronounced dysregulation of the kynurenine pathway directly to refined carbohydrates and vegetable oils in humans overstates the current clinical evidence. Narrative and systematic reviews in nutritional psychiatry note that while broad dietary patterns plausibly modulate inflammation, oxidative stress, and tryptophan-kynurenine metabolism, the body of evidence connecting specific dietary elements like refined carbohydrates or vegetable oils to these pathway shifts consists primarily of theoretical models and preclinical animal studies.

0:26:43Georgia Edeoverstatedlow

Under the influence of neuroinflammation, glutamate levels can spike up to one hundred times baseline, causing excitotoxicity that damages the blood-brain barrier, hippocampus, and mitochondrial membranes.

"and you have steep spikes in glutamate, this neurotransmitter called glutamate, up to a hundred times its previous baseline. And then you can develop something called glutamate excitotoxicity. So glutamate is the brain's gas pedal; it's the brain's primary excitatory neurotransmitter. And so when you've got high levels of glutamate—this is all just coming from inflammation and oxidative stress from eating the wrong way—when you get these big surges in glutamate, glutamate is directly physically damaging to all critical structures of the brain, including the blood-brain barrier, including the hippocampus, the brain's learning and memory center, including the delicate membranes of the mitochondria" (said at 0:26:43)

The mechanistic components of the claim are well-documented in preclinical and neurotrauma models: elevated extracellular glutamate causes excitotoxicity through calcium overload, leading to mitochondrial membrane disruption, hippocampal neuronal injury, and blood-brain barrier dysfunction, and this interacts bidirectionally with neuroinflammation. However, framing this as a 100-fold surge in baseline glutamate driven primarily by diet-induced systemic inflammation is an overstatement. Massive multi-fold extracellular glutamate spikes are typically documented in acute, catastrophic insults such as status epilepticus, severe traumatic brain injury, or cerebral ischemia rather than ordinary dietary inflammation.

0:31:12Georgia Edeoverstatedmoderate

By the time subtle signs of memory problems are noticed, the brain can already have lost up to 25% of its glucose processing capacity.

"And so by the time you notice any signs, even subtle signs of memory problems, the brain can already have lost up to 25% of its glucose processing capacity." (said at 0:31:12)

FDG-PET neuroimaging demonstrates that cerebral glucose hypometabolism begins presymptomatically and is present in mild cognitive impairment (MCI) and early Alzheimer's disease. However, quantitative PET studies indicate that at the earliest stages of subtle cognitive impairment (MCI), glucose metabolism is reduced by roughly 7% to 15% in specific vulnerable brain regions (such as the cingulate and temporoparietal cortex), rather than an overall 25% loss across the entire brain. Regional reductions approaching or exceeding 20% to 25% are typically observed in established early-to-moderate Alzheimer's dementia rather than at the very first subtle emergence of memory symptoms.

0:50:37Georgia Edeoverstatedmoderate

If a person's waist circumference is more than half their height, there is roughly a 90% chance they have insulin resistance.

"if your waist circumference is more than half your height, there's about a 90% chance that you've got insulin resistance." (said at 0:50:37)

A waist circumference greater than half of height (waist-to-height ratio ≥ 0.5) is a well-established anthropometric screening threshold for central adiposity and insulin resistance. However, claiming that exceeding this cutoff gives 'about a 90% chance' of having insulin resistance overstates its diagnostic accuracy. ROC curve analyses evaluate waist-to-height ratio with an area under the curve (AUC) around 0.71 to 0.74, with optimal cut-off values around 0.50-0.53. In general populations, a screening threshold of 0.5 yields moderate diagnostic performance rather than a ~90% positive predictive value (post-test probability), meaning that while it is an effective screening tool, having a ratio over 0.5 does not equate to a 90% certainty of having insulin resistance.

0:52:43Georgia Edeoverstatedmoderate

A fasting triglyceride level over 100 mg/dL (or over 1.1 mmol/L) indicates excess dietary carbohydrate consumption relative to one's metabolic capacity.

"If the triglycerides are over 100 milligrams per deciliter, or over 1.1 millimoles if you're outside the United States, then that's a clue that you're eating too much carbohydrate for your personal metabolism." (said at 0:52:43)

While carbohydrate restriction lowers circulating triglycerides and high intakes of refined carbohydrates or sugars can stimulate hepatic de novo lipogenesis and elevate triglycerides—especially in individuals with insulin resistance—fasting triglycerides exceeding 100 mg/dL (1.1 mmol/L) do not uniquely or definitively indicate excess dietary carbohydrate intake. Standard clinical guidelines define normal fasting triglycerides as <150 mg/dL (<1.7 mmol/L). Furthermore, elevated triglycerides are multifactorial, commonly driven by total caloric surplus, adiposity, alcohol intake, genetic variations in lipid clearance, hypothyroidism, renal disease, and various medications, rather than solely dietary carbohydrate exceeding metabolic capacity.

1:04:30David Perlmutter (host)overstatedlow

Psychiatric disorders and cognitive decline have significant metabolic underpinnings, and improving metabolic health through targeted dietary interventions can lead to substantial clinical improvements without notable side effects.

"these illnesses that we talked about today have a very strong metabolic underpinning. And when we pay attention to that and redirect our metabolic health through the types of interventions that we talked about on the podcast today, we can expect to see some significant improvements without concern with respect to things like side effects." (said at 1:04:30)

While emerging research in metabolic psychiatry shows promising link between metabolic health and psychiatric or cognitive symptoms, the claim overstates the current level of scientific certainty and clinical evidence. Small open-label pilot trials (e.g., n=23 in individuals with schizophrenia or bipolar disorder) demonstrate metabolic enhancements (such as a 27% drop in HOMA-IR) alongside reductions in psychiatric symptom severity (32% decrease in Brief Psychiatric Rating Scale scores). Similarly, a small randomized crossover trial in Alzheimer's disease found significant improvements in daily function and quality of life, with mild side effects. However, critical systematic reviews emphasize that the majority of clinical evidence in mental health consists of small, single-arm or uncontrolled studies prone to expectation bias and confounding factors, with randomized controlled trial evidence remaining sparse and preliminary.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.